Vatelizumab
Vatelizumab is being developed as a treatment for relapsing MS, but the phase 2 trial was terminated early in 2016. We don't yet know the next steps for this treatment.
- Current phase of trial:
- Phase 2
- Type of MS:
- Relapsing MS
Find out more about vatelizumab
How does vatelizumab work?
Vatelizumab is an antibody, just like those found in the immune system (where antibodies help fight infection). We don't fully know hoow vatelizumab works, but it is thought that it could alter the behaviour of immune cells, preventing them from entering the brain and spinal cord and therefore stopping them from attacking and damaging myelin.
How is vatelizumab taken?
Vatelizumab is an intravenous infusion.
Latest vatelizumab research
EMPIRE trial
This phase 2 trial began in 2014 and aimed to test the safety and benefits of four doses of vatelizumab. It compared the treatment against a placebo in 112 people with relapsing MS.
The trial was terminated in 2016. We don't have any further details at this time.
What are the side effects of vatelizumab?
Side effects were due to be measured in the EMPIRE trial, but we don't have details as the trial was terminated early.
How does vatelizumab compare with current therapies?
Vatelizumab hasn’t yet been directly compared with other treatments for relapsing MS.
When will vatelizumab be available?
The phase 2 trial of vatelizumab was terminated early in 2016. We don't yet know the next steps for the treatment – we will keep you updated with the latest vatelizumab news.
